On Friday last week Regeneron released Q1 figures which were ahead of expectations as Eylea surprised positively once again. Be it for Eylea ex-US, Zaltrap or other collaborations with Sanofi, Regeneron simply reiterated what partners had already said. Besides Q1 however, Regeneron announced that it was regaining rights for the PDGF and ANG2 antibodies in ophthalmology from Sanofi against upfront and milestones payments as well as royalties on sales.
Full report available to subscribers
Please contact email@example.com